Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age
We aimed to investigate the effectiveness of oncological treatments in metastatic CRC related to comorbidities and age. This retrospective study included 1105 patients from three oncological centers. aaCCI and CCI was available from 577 patients. An aaCCI > 3 was of the highest predictive value c...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/9/2091 |
| _version_ | 1797536250561822720 |
|---|---|
| author | Dora Niedersüß-Beke Manuel Orlinger David Falch Cordula Heiler Gudrun Piringer Josef Thaler Wolfgang Hilbe Andreas Petzer Holger Rumpold |
| author_facet | Dora Niedersüß-Beke Manuel Orlinger David Falch Cordula Heiler Gudrun Piringer Josef Thaler Wolfgang Hilbe Andreas Petzer Holger Rumpold |
| author_sort | Dora Niedersüß-Beke |
| collection | DOAJ |
| description | We aimed to investigate the effectiveness of oncological treatments in metastatic CRC related to comorbidities and age. This retrospective study included 1105 patients from three oncological centers. aaCCI and CCI was available from 577 patients. An aaCCI > 3 was of the highest predictive value compared to other aaCCI-levels, CCI or age (<i>p</i> < 0.001 for all). Treatment (best supportive care (BSC), systemic treatment only (STO) and resection of metastases (ROM)) significantly prolonged survival in patients with aaCCI > 3 (STO: HR 0.39, CI 0.29–0.51; ROM: HR 0.16, CI 0.10–0.24) and patients older than 70 years (STO: HR 0.56, CI 0.47–0.66; ROM: HR 0.23, 0.18–0.30). Median overall survival was shorter in patients with aaCCI or age > 70 years and interaction for treatment type not significant for aaCCI, but significant for age older or younger than 70 years (STO: <i>p</i> = 0.01; ROM <i>p</i> = 0.02). BSC is more often considered as optimal care for patients with an aaCCI > 3 (37.6% vs. 12.4%; <i>p</i> < 0.001) or age > 70 years (35.7% vs. 11.2%; <i>p</i> < 0.001). Older patients or patients with comorbidities benefit from cancer-specific therapy independently of their age and comorbidities. |
| first_indexed | 2024-03-10T11:57:00Z |
| format | Article |
| id | doaj.art-5fc49537697f4a008255c9595e665960 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:57:00Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5fc49537697f4a008255c9595e6659602023-11-21T17:12:16ZengMDPI AGCancers2072-66942021-04-01139209110.3390/cancers13092091Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and AgeDora Niedersüß-Beke0Manuel Orlinger1David Falch2Cordula Heiler3Gudrun Piringer4Josef Thaler5Wolfgang Hilbe6Andreas Petzer7Holger Rumpold8Department of Internal Medicine I, Wilhelminenspital, 1160 Vienna, AustriaDepartment of Hematology and Medical Oncology, Ordensklinikum Linz, 4010 Linz, AustriaDepartment of Internal Medicine I, Wilhelminenspital, 1160 Vienna, AustriaDepartment of Internal Medicine I, Wilhelminenspital, 1160 Vienna, AustriaDepartment of Internal Medicine IV, Hospital Wels-Grieskirchen, 4600 Wels, AustriaDepartment of Internal Medicine IV, Hospital Wels-Grieskirchen, 4600 Wels, AustriaDepartment of Internal Medicine I, Wilhelminenspital, 1160 Vienna, AustriaDepartment of Hematology and Medical Oncology, Ordensklinikum Linz, 4010 Linz, AustriaMedical Faculty, Johannes Kepler University Linz, 4020 Linz, AustriaWe aimed to investigate the effectiveness of oncological treatments in metastatic CRC related to comorbidities and age. This retrospective study included 1105 patients from three oncological centers. aaCCI and CCI was available from 577 patients. An aaCCI > 3 was of the highest predictive value compared to other aaCCI-levels, CCI or age (<i>p</i> < 0.001 for all). Treatment (best supportive care (BSC), systemic treatment only (STO) and resection of metastases (ROM)) significantly prolonged survival in patients with aaCCI > 3 (STO: HR 0.39, CI 0.29–0.51; ROM: HR 0.16, CI 0.10–0.24) and patients older than 70 years (STO: HR 0.56, CI 0.47–0.66; ROM: HR 0.23, 0.18–0.30). Median overall survival was shorter in patients with aaCCI or age > 70 years and interaction for treatment type not significant for aaCCI, but significant for age older or younger than 70 years (STO: <i>p</i> = 0.01; ROM <i>p</i> = 0.02). BSC is more often considered as optimal care for patients with an aaCCI > 3 (37.6% vs. 12.4%; <i>p</i> < 0.001) or age > 70 years (35.7% vs. 11.2%; <i>p</i> < 0.001). Older patients or patients with comorbidities benefit from cancer-specific therapy independently of their age and comorbidities.https://www.mdpi.com/2072-6694/13/9/2091colorectal cancermetastasesreal-lifetreatmentcomorbiditieselderly |
| spellingShingle | Dora Niedersüß-Beke Manuel Orlinger David Falch Cordula Heiler Gudrun Piringer Josef Thaler Wolfgang Hilbe Andreas Petzer Holger Rumpold Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age Cancers colorectal cancer metastases real-life treatment comorbidities elderly |
| title | Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age |
| title_full | Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age |
| title_fullStr | Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age |
| title_full_unstemmed | Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age |
| title_short | Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and Age |
| title_sort | clinical effectiveness of oncological treatment in metastatic colorectal cancer is independent of comorbidities and age |
| topic | colorectal cancer metastases real-life treatment comorbidities elderly |
| url | https://www.mdpi.com/2072-6694/13/9/2091 |
| work_keys_str_mv | AT doraniedersußbeke clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT manuelorlinger clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT davidfalch clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT cordulaheiler clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT gudrunpiringer clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT josefthaler clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT wolfganghilbe clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT andreaspetzer clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage AT holgerrumpold clinicaleffectivenessofoncologicaltreatmentinmetastaticcolorectalcancerisindependentofcomorbiditiesandage |